西地那非对严重早发性胎儿生长受限妊娠孕妇母体血流动力学的影响:多中心随机安慰剂对照双盲试验的计划亚组分析
本研究为英国多中心随机安慰剂对照双盲试验的心血管亚组分析,纳入135例严重早发性胎儿生长受限孕妇,随机接受西地那非25 mg每日三次或安慰剂至妊娠32+0周或分娩。结果显示西地那非在给药后1-2小时较安慰剂增加母体心率、降低收缩压和主动脉脉搏波传导速度,这些变化短暂、轻微,符合预期血管扩张效应,对母体无短期或长期临床影响。
要点
- 西地那非25 mg每日三次在严重早发性胎儿生长受限孕妇中增加心率、降低血压和动脉僵硬度。
- 上述血流动力学变化短暂、轻微,符合预期血管扩张效应,对母体无短期或长期临床影响。
核心结论
- 西地那非25 mg每日三次在严重早发性胎儿生长受限妊娠中增加心率、降低血压并降低动脉僵硬度,这些变化短暂、轻微,符合预期血管扩张效应,对母体无短期或长期临床影响。
研究设计与样本
- 英国多中心随机安慰剂对照双盲试验的心血管亚组分析,纳入135例单胎妊娠严重早发性胎儿生长受限孕妇(诊断孕周22+0至29+6周),随机分配接受西地那非25 mg每日三次(n=69)或安慰剂(n=65)至妊娠32+0周或分娩。
主要发现
- 随机分组后1-2小时,西地那非组心率较基线增加5.00 bpm(95%CI 1.00-12.00 bpm),安慰剂组增加1.25 bpm(95%CI -5.38至7.88 bpm),组间差异P=0.004。
- 随机分组后1-2小时,西地那非组收缩压较基线降低4.13 mmHg(95%CI -9.94至1.44 mmHg),安慰剂组降低2.75 mmHg(95%CI -7.50至5.25 mmHg),组间差异P=0.048。
- 校正母体平均动脉压后,西地那非组主动脉脉搏波传导速度较基线降低0.90 m/s(95%CI -1.31至-0.51 m/s),安慰剂组降低0.26 m/s(95%CI -0.75至0.59 m/s),组间差异P=0.001。
- 随机分组后1-2小时,西地那非组每平方米体表面积每搏输出量指数较基线降低5.50 mL/m2(95%CI -11.00至-0.50 mL/m2),安慰剂组变化0.00 mL/m2(95%CI -5.00至4.00 mL/m2),组间差异P=0.056,未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Fetal growth restriction (FGR) is associated with maternal cardiovascular changes. Sildenafil, a phosphodiesterase type-5 inhibitor, potentiates the actions of nitric oxide, and it has been suggested that it alters maternal hemodynamics, potentially improving placental perfusion. Recently, the Dutch STRIDER trial was stopped prematurely owing to excess neonatal mortality secondary to pulmonary hypertension. The main aim of this study was to investigate the effect of sildenafil on maternal hemodynamics in pregnancies with severe early-onset FGR. METHODS: This was a cardiovascular substudy within a UK multicenter, placebo-controlled trial, in which 135 women with a singleton pregnancy and severe early-onset FGR (defined as a combination of estimated fetal weight or abdominal circumference below the 10th centile and absent/reversed end-diastolic flow in the umbilical artery on Doppler velocimetry, diagnosed between 22 + 0 and 29 + 6 weeks' gestation) were assigned randomly to receive either 25 mg sildenafil three times daily or placebo until 32 + 0 weeks' gestation or delivery. Maternal blood pressure (BP), heart rate (HR), augmentation index, pulse wave velocity (PWV), cardiac output, stroke volume (SV) and total peripheral resistance were recorded before randomization, 1-2 h and 48-72 h post-randomization, and 24-48 h postnatally. For continuous data, analysis was performed using repeated measures ANOVA methods including terms for timepoint, treatment allocation and their interaction. RESULTS: Included were 134 women assigned randomly to sildenafil (n = 69) or placebo (n = 65) who had maternal BP and HR recorded at baseline. At 1-2 h post-randomization, compared with baseline values, sildenafil increased maternal HR by 4 bpm more than did placebo (mean difference, 5.00 bpm (95% CI, 1.00-12.00 bpm) vs 1.25 bpm (95% CI, -5.38 to 7.88 bpm); P = 0.004) and reduced systolic BP by 1 mmHg more (mean difference, -4.13 mmHg (95% CI, -9.94 to 1.44 mmHg) vs -2.75 mmHg (95% CI, -7.50 to 5.25 mmHg); P = 0.048). Even after adjusting for maternal mean arterial pressure, sildenafil reduced aortic PWV by 0.60 m/s more than did placebo (mean difference, -0.90 m/s (95% CI, -1.31 to -0.51 m/s) vs -0.26 m/s (95% CI, -0.75 to 0.59 m/s); P = 0.001). Sildenafil was associated with a non-significantly greater decrease in SV index after 1-2 h post-randomization than was placebo (mean difference, -5.50 mL/m2 (95% CI, -11.00 to -0.50 mL/m2 ) vs 0.00 mL/m2 (95% CI, -5.00 to 4.00 mL/m2 ); P = 0.056). CONCLUSIONS: Sildenafil in a dose of 25 mg three times daily increases HR, reduces BP and reduces arterial stiffness in pregnancies complicated by severe early-onset FGR. These changes are short term, modest and consistent with the anticipated vasodilatory effect. They have no short- or long-term clinical impact on the mother. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Khalil A, Sharp A, Cornforth C, et al. Effect of sildenafil on maternal hemodynamics in pregnancies complicated by severe early-onset fetal growth restriction: planned subgroup analysis from a multicenter randomized placebo-controlled double-blind trial. Ultrasound Obstet Gynecol. 2020. PMID: 31432556. doi:10.1002/uog.20851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。